Simply put, extending orphan drug designation in this manner would have been inconsistent with the intention of the Orphan Drug Act.
Lisa Blunt Rochester
The Public Record
Lisa Blunt Rochester is an American politician serving as the U.S. Representative for Delaware's at-large congressional district since January 3, 2017. A member of the Democratic Party, she is the first woman and the first person of color to hold this position in Delaware. Throughout her tenure, she has focused on issues such as healthcare, education, and economic development, advocating for policies that support working families and promote social justice.
Climate change is fueling extreme weather, which impacts every part of our country.
The science is clear; we must transition to a 100 percent clean economy, energy economy, as quickly as possible if we are going to avoid the worst impacts of climate change.
And so I am strongly in support of this bill, and I hope that my colleagues will also recognize the time is now.
We are obviously interested in making sure that this new regulatory program would be implemented efficiently.
Does section 6 of the bill give EPA sufficient authority to address refrigerant management and work to minimize emissions?
My bill would cap out-of-pocket costs, including premiums, deductibles, and copays, so no one is spending their whole paycheck for healthcare.
A decade ago, this very subcommittee debated one of the country's most sweeping and comprehensive pieces of healthcare policy, the Affordable Care Act.
Climate change is real, that we must address it on a global level, and that the United States must be a leader.
I am concerned that, increasingly, the increasingly global market that FDA has is--you are not equipped to properly oversee the safety of cosmetic and personal care products.
I have long believed that the FDA's authority in this area is woefully inadequate to keep up with an industry that has evolved considerably since Congress has last legislated in this space.
I think we can all agree that we should be working together to help achieve the FDA's mission of protecting and advancing public health.
There are so many reasons. Number one, many people in my State say they can't even find affordable housing.
Today's hearing is important, and I am glad that we are looking at the policy solutions we need to prioritize and protect frontline communities that are hit worst by impacts from both pollution and climate change.
The science is clear: We must transition to a 100 percent clean energy economy as quickly as possible and if we are going to avert the impacts of climate change.
It is important that people have confidence and faith in these institutions, and the way we answer questions exhibits that confidence and faith.
This hearing is really significant, and as Ms. Oyama said, I want us to not forget the important things that the internet has provided to us.
Thank you, Mr. Chairman and thank you to Ranking Member Tomkus [sic]--Shimkus for holding today's hearing.
There is agreement that the CFATS program needs to continue, needs to continue long term.
I especially want to acknowledge Representative Kelly for her leadership in this important issue.
We, as a country, want to be improving, not just maintaining or going backwards.





